Compare Inovio Pharmaceuticals Inc (INO) vs Alliant Energy Corporation (LNT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Alliant Energy Corporation — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $89.27M), while Alliant Energy Corporation trades at $73.98 (market cap $19.10B). The key difference: Alliant Energy Corporation is far larger — about 214× Inovio Pharmaceuticals Inc's market cap, and Alliant Energy Corporation pays a 2.89% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | LNT | |
|---|---|---|
Market Cap | $89.27M | $19.10B |
Sector | Health | Utilities |
52-Week High | $2.87 | $78.03 |
52-Week Low | $1.05 | $63.62 |
Enterprise Value | $60.28M | $30.83B |
Dividend Yield | — | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.10, down 1.79% recently, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 in 2025 and a net loss of $84.95 million, resulting in negative profitability margins. Recent news highlights an ongoing FDA review for INO-3107 with a PDUFA date of October 30, 2026, while shareholder litigation investigations emerge. Cash flow remains negative, though operating expenses have declined.
The investment case hinges on the binary FDA decision for INO-3107, offering potential upside if approved, but carries high risk due to persistent losses, negative cash flow, and legal scrutiny. Analyst consensus is moderately bullish with 53% buy ratings, but fundamental weaknesses and technical bearishness suggest cautious positioning is warranted.
Alliant Energy (LNT) trades at $73.11, down 2.29% on the day, with a bullish technical outlook and strong analyst support. The stock shows steady revenue growth, improving net income margins to 18.58% in 2025, and consistent dividend payments. Recent news highlights its $13.4 billion clean energy investment plan targeting 5-7% annual earnings growth, driven by data center demand and grid modernization initiatives.
LNT presents a favorable risk-reward profile with a consensus price target of $78.50, offering 7.4% upside. Key risks include rising debt levels and execution of capital-intensive projects. The bullish analyst consensus (52% Buy) and institutional confidence support long-term growth, though investors should monitor interest rate sensitivity and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Alliant Energy Corporation
Alliant Energy is the parent of two regulated utilities, Interstate Power and Light and Wisconsin Power and Light, serving nearly 1 million electricity and natural gas customers and approximately 420,000 natural gas-only customers. Both subsidiaries engage in the generation and distribution of electricity and the distribution and transportation of natural gas. Alliant also owns a 16% interest in American Transmission Co.
Read more on LNT →
